Authors
Latest:
Dr Lazzaro on Lung Cancer Screening in High-Risk IndividualsRichard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.
Latest:
Emerging Treatments for MyelofibrosisAndrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.
Latest:
Building the Optimal Patient Experience Takes Planning and EffortEnsuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.
Latest:
Cancer Researchers and Student Athletes Are “Here to Win” for Innovation, Discovery, and HopeBuilding an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.
Latest:
Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast CancerNusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.
Latest:
Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon CancerJeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.
Latest:
Anticipating Key Studies and Pipeline Treatments in mCRC LandscapeThe experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Latest:
Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid TumorsJ. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.
Latest:
Dr. Schweizer on the Results of the HERO Trial in Prostate CancerMichael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.
Latest:
Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple MyelomaShuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.
Latest:
Dr Piulats on Predictive Biomarkers for Treatment With Talazoparib/Enzalutamide in mCRPCJosep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.
Latest:
Dr Khan on the Effects of Financial Toxicity on Survival Outcomes in Patients With CancerHiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.
Latest:
Biomarkers Help Predict the Role of Chemotherapy in Biologic AgingStimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.
Latest:
Delivering Long-Term Results for Blood Cancer PatientsWhile great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.
Latest:
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast CancerTreatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
Latest:
Dr. Roland on Findings From a Phase 2 Study With Neoadjuvant Checkpoint Blockade in SarcomaChristina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Latest:
Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian CancerBritt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.
Latest:
Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical CancerLeslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.
Latest:
Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast CancerShakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced MelanomaSajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.
Latest:
The Future of Liver Function Assessments in HCCExperts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.
Latest:
5 Tips for a First-Year FellowChristopher Su, MD, MPH, highlights 5 tips for first-year oncology fellows.
Latest:
The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center DisasterInvestigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.
Latest:
Dr. Davies on the Potential Utility of ERK Inhibitors in MelanomaMichael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.
Latest:
Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial CarcinomaVignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.
Latest:
Dr Leick on Limitations Associated With CAR T-Cell Therapy in Hematologic MalignanciesMark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.
Latest:
Dr Eisfeld on Timing of Molecular Testing and the Start of Treatment in AMLAnn-Kathrin Eisfeld, MD, discusses factors to consider when deciding whether to start treatment right away or wait for molecular testing results in patients with acute myeloid leukemia.
Latest:
Basal Cell Carcinoma Clinical PearlsDrs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.
